Skip to Main Content

A bipartisan bill aimed at helping terminally ill patients gain access to experimental medicines would leave intact the controversial role of the Food and Drug Administration, a notion that will likely upset backers of the so-called right-to-try movement.

The draft legislation, which is being developed with help from the FDA, also includes a provision that seeks to reassure anxious drug makers about making their treatments available, but to what extent this move makes the effort easier to forge a compromise is uncertain.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Ah, an interesting point of view – “we don’t believe the government should have a role in that decision-making process once a drug is determined to be safe enough to give to people in human trials,” said Starlee Coleman, a spokeswoman for the Goldwater Institute” – but there is a true difference between safe enough for trials and ‘safe and effective.’
    Trials do surprise, don’t they? I will demure from providing examples.

Comments are closed.